F8 and hemophilia A: Notably, the experts reported no inhibitor formation for any previously treated patient on EHL products, rFVIIIFc or recombinant pegylated FVIII (rFVIIIpeg), or the non-factor replacement product, emicizumab; note: anti-emicizumab antibodies, including some with emicizumab-neutralizing activity, have been reported in a few people with hemophilia A treated with emicizumab [26–28].